Tseng Lab on the move? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Tseng Lab on the move?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VinceC who wrote (163)	7/19/1998 12:01:00 AM
From: muddphudd	Read Replies (1) of 251

I spoke with Rifat Pamukcu (Chief Scientific Officer at CPI) this week. Very pleasant fellow. He said that they have 500 in-house derivatives of FGN-1, some of which are 20,000 times more potent than FGN-1. As you know, FGN-1 is a derivative of Sulindac, an NSAID. However, it does not possess the COX-1 or COX-II activity of Sulindac. Hence, it is not involved as an anti-inflammatory and it does not cause GI upset like most other NSAIDs. How it actually works it "top-seret". It works by inducing apoptosis in cancer cells, but HOW it does this remains a mystery (at least to the public). Pamukcu said that it functions independent of the p53 or bcl-2 pathways. Supposedly, they will publish papers soon describing exactly what the intracellular target of FGN-1 is. He did say that they are in discussion with some big pharma for the marketing of FGN-1 for colon cancer. No names, of course. He said that they expect to be publicly trading by late September.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next